Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Ribera JM, et al. Among authors: gimenez conca a. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. Blood. 2021. PMID: 33150388 Free article. Clinical Trial.
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.
Ribera JM, Morgades M, Genescà E, Chapchap EC, Montesinos P, Acuña-Cruz E, Gil C, García-Cadenas I, Barba P, González-Campos J, Queipo de Llano MP, Torrent A, Ribera J, Granada I, Bernal T, Díaz-Beyá M, Amigo ML, Coll R, Tormo M, Vall-Llovera F, Gómez-Centurión I, Sánchez-Sánchez MJ, Soria B, Cladera A, Artola MT, Garcia-Guiñon A, Giménez-Conca A, Amador ML, Martínez-Sánchez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, Llorente L, García-Boyero R, Ciudad J, Feliu E, Orfao A; on behalf of the PETHEMA Group. Ribera JM, et al. Among authors: gimenez conca a. Hematol Oncol. 2021 Oct;39(4):529-538. doi: 10.1002/hon.2910. Epub 2021 Aug 18. Hematol Oncol. 2021. PMID: 34405901
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy.
Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, Gimenez Conca A, Castillo TBD, Girshova L, Martelli MP, Guvenc B, Delgado A, Duan Y, Garbayo Guijarro B, Llamas C, Lee JH. Miyamoto T, et al. Among authors: gimenez conca a. Leuk Lymphoma. 2022 Apr;63(4):928-938. doi: 10.1080/10428194.2021.2002321. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147482
Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F, Gutierrez Acevedo MN, Rossi MS, Gimenez Conca AD, Otero V, Arbelbide JA, Michelángelo H. Angriman F, et al. Among authors: gimenez conca ad. Turk J Haematol. 2015 Jun;32(2):193-4. doi: 10.4274/tjh.2014.0211. Turk J Haematol. 2015. PMID: 26316496 Free PMC article. No abstract available.